Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Eisner

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
International Journal of Obesity (2005)|May 2, 2007
Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndromeC M Bruns, S T Baum, R J Colman, et al.
Database : the Journal of Biological Databases and Curation|April 30, 2010
Phenol-Explorer: an online comprehensive database on polyphenol contents in foodsV Neveu, J Perez-Jiménez, F Vos, et al.
Journal of Psychiatric Practice|November 24, 2011
Mindfulness-based cognitive therapy for bipolar disorder: effects on cognitive functioningJonathan P Stange, Lori R Eisner, Britta K Hölzel, et al.
CNS Neuroscience & Therapeutics|November 11, 2011
Mindfulness-based cognitive therapy for nonremitted patients with bipolar disorderThilo Deckersbach, Britta K Hölzel, Lori R Eisner, et al.
Breast Cancer Research and Treatment|September 30, 2018
Male breast cancer: a disease distinct from female breast cancerAyca Gucalp, Tiffany A Traina, Joel R Eisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerShilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Breast Cancer Research and Treatment|May 11, 2018
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancerAditya Bardia, Ayca Gucalp, Noashir DaCosta, et al.
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Molecular Cancer Therapeutics|March 16, 2021
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast CancerJessica L Christenson, Kathleen I O'Neill, Michelle M Williams, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2024
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based ImmunotherapiesKirk D Beebe, Joel R Eisner, John Guo, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Obesity (2005)|May 2, 2007
Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndromeC M Bruns, S T Baum, R J Colman, et al.
Database : the Journal of Biological Databases and Curation|April 30, 2010
Phenol-Explorer: an online comprehensive database on polyphenol contents in foodsV Neveu, J Perez-Jiménez, F Vos, et al.
Journal of Psychiatric Practice|November 24, 2011
Mindfulness-based cognitive therapy for bipolar disorder: effects on cognitive functioningJonathan P Stange, Lori R Eisner, Britta K Hölzel, et al.
CNS Neuroscience & Therapeutics|November 11, 2011
Mindfulness-based cognitive therapy for nonremitted patients with bipolar disorderThilo Deckersbach, Britta K Hölzel, Lori R Eisner, et al.
Breast Cancer Research and Treatment|September 30, 2018
Male breast cancer: a disease distinct from female breast cancerAyca Gucalp, Tiffany A Traina, Joel R Eisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerShilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Breast Cancer Research and Treatment|May 11, 2018
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancerAditya Bardia, Ayca Gucalp, Noashir DaCosta, et al.
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Molecular Cancer Therapeutics|March 16, 2021
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast CancerJessica L Christenson, Kathleen I O'Neill, Michelle M Williams, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2024
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based ImmunotherapiesKirk D Beebe, Joel R Eisner, John Guo, et al.
Pageof 7